Centocor's golimumab approved in second market, the US, for arthritis indications
This article was originally published in Scrip
Executive Summary
Centocor Ortho Biotech's human anti-TNF MAb, golimumab (Simponi), has been approved for marketing in the US for three immune-related arthritis conditions – moderate-to-severe rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.